V enous thromboembolism, composed of deep vein thrombosis (DVT) and pulmonary embolism, represents a worldwide major health issue and is a leading cause of cardiovascular death. 1 Since the past decade, the prevalence continues to increase, reaching >400 per 100 000. 2 
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The activation of proinflammatory mechanisms during DVT has been emphasized by several in vitro and in vivo studies. Markers of inflammation such as interleukin-6, interleukin-8, P-selectin, chemokine ligand 2 (CCL2), and C-reactive protein are associated with thrombosis development. [3] [4] [5] [6] [7] In addition, the important role of leukocytes in the formation of venous thrombosis has recently been demonstrated. Hence, von Brühl et al 8 demonstrated that neutrophils and monocytes are recruited early and actively participate to venous thrombosis formation after partial ligation of the inferior vena cava. They found that neutrophils and monocytes contribute to thrombosis by triggering FXII-dependent coagulation and delivering tissue factor (TF), respectively. They also demonstrated that expression of P-selectin by the endothelium supported the recruitment of leukocytes. Circulating monocytes are the major source of TF-mediated coagulation. 8, 9 After vessel injury, activated platelet and endothelial cells release cytokines, which trigger TF expression from monocytes. In patients, blood monocyte counts were associated with an increased risk of venous thrombosis. July 2017
The recruitment of monocytes involves the coordinated secretion of chemokines by the activated endothelium and the expression of chemokine counter-receptors by monocytes. CCL2/CCR2 (C-C chemokine receptor type 2), CX3CL1/ CX3CR1 (CX3C chemokine receptor 1), and CCL5/CCR5 are the 3 main chemokines and chemokine receptors that have been involved in the recruitment of monocytes in vascular disease. hi monocytes show a patrolling behavior. They migrate poorly to sites of acute inflammation and accumulate in noninflamed peripheral tissue such as the spleen, the lungs, and the liver. Inflammatory monocytes are recruited during sterile inflammation after injury and during DVT. 14, 15 However, the contribution of the monocyte subsets to venous thrombosis has been poorly studied.
Gas6 (growth arrest-specific 6)-deficient (Gas6 −/− ) mice are protected from lethal venous thromboembolism and develop smaller thrombi. 16, 17 This can be partially explained by a role of Gas6 both in platelet aggregation and in endothelial cell activation through TF expression. [17] [18] [19] [20] Interestingly, the absence of Gas6 does not cause excessive bleeding, which suggests that Gas6 may be an attractive antithrombotic target. Gas6 amplifies endothelial cell activation and promotes the recruitment of platelets and leukocytes to the endothelial cell membrane. 21 Thus, we hypothesize that Gas6 may be involved in monocyte recruitment during venous thrombosis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Gas6 Promotes the Recruitment of Inflammatory Monocytes During Venous Thrombosis
To investigate the role of Gas6 in the recruitment of monocytes during venous thrombosis, we induced DVT in mice using both the FeCl 3 and the flow restriction models in the inferior vena cava. 8 We had previously demonstrated that thrombus size is reduced in Gas6 −/− mice compared with wild type (WT) using the FeCl 3 model. 9, 17 Using the flow restriction model, we confirmed that absence of Gas6 results in the reduction of venous thrombosis ( Figure 1A ). Importantly, we showed that monocyte recruitment is reduced in Gas6 −/− mice compared with WT mice in both DVT models ( Figure 1B and 1C) . The absence of Gas6 did not affect neutrophil recruitment in FeCl 3 -induced venous thrombosis ( Figure 1D) hi monocytes ( Figure 1E and 1F). Immunofluorescence staining within thrombi confirmed that Gas6 deficiency reduced the recruitment of CCR2-expressing monocytes ( Figure I in the online-only Data Supplement). These data suggest that Gas6 is involved in the recruitment of inflammatory (CCR2 hi CX 3 CR1 lo ) monocytes during thrombus formation.
Inflammatory Monocytes Contribute to Venous Thrombus Formation
Monocytes were depleted in WT mice using clodronate liposomes. Clodronate treatment significantly reduced CD11b Inflammatory monocytes were specifically depleted using a CCR2 antibody 24 hours before thrombus induction. 22 Flow cytometry analysis showed that circulating inflammatory (Ly6C hi CCR2 hi CX 3 CR1 lo ) monocytes were successfully depleted from the blood of WT mice injected with the CCR2 antibody ( Figure IIIA in the online-only Data Supplement). Importantly, depletion of inflammatory monocytes reduced thrombus size, area, and weight (Figure 2Ci through 2Ciii) . WT mice were also injected with an antibody against CCR2 ligand, CCL2. MOMA-2 staining within thrombi showed that the CCL2-blocking antibody reduced monocyte recruitment ( Figure 2D ). In vivo blockade of CCL2 also reduced thrombus size and area (Figure 2Ei and 2Eii). CCL2 depletion also reduced the number of inflammatory monocytes recruited to the thrombus in WT mice ( Figure IIIB in the online-only Data Supplement). These results suggest that Gas6 promotes the recruitment of inflammatory monocytes during DVT.
Gas6 Is Required for ThrombinInduced CCR2/CCL2 Expression
Given the role of Gas6 in venous thrombosis and the importance of inflammatory monocytes described above, we analyzed the role of Gas6 in thrombin-induced expression of CCR2 in bone marrow-derived monocytes and CCL2 in endothelial cells in vitro.
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CCL2
chemokine ligand 2 Thrombin upregulated CCR2 mRNA and protein expression in WT but not Gas6 −/− monocytes (Figure 3Ai and 3Aii). mRNA expression of CCL2 was induced in WT but not in Gas6 −/− endothelial cells after thrombin treatment (Figure 3Bi ). CCL2 production was increased by thrombin in culture media from WT but not from Gas6 −/− endothelial cells (Figure 3Bii ). These data suggest that Gas6 is required for thrombin-induced CCR2 and CCL2 expression. Thus, we tested whether the thrombin receptor, PAR-1 (protease activated receptor 1), was involved in Gas6-dependent CCR2 and CCL2 expression. Treatment of WT monocytes and endothelial cells with a PAR-1 antagonist, SCH79797, inhibited the thrombin-induced CCR2 and CCL2 expression ( Figure IVA and IVB in the online-only Data Supplement). However, PAR-1 mRNA expression was similar between Gas6 −/− and WT monocytes or endothelial cells (Figure inferior vena cava and IVD in the online-only Data Supplement). These data suggest that thrombin induces CCL2 in endothelial cells and CCR2 in monocytes through PAR-1 in a Gas6-dependent manner but not through the regulation of PAR-1 expression.
Gas6 Is Involved in CCR2/CCL2-Dependent Monocyte Migration
As demonstrated above, thrombin failed to induce CCR2 expression in monocytes lacking Gas6. Thus, we hypothesize that the migratory capacity of Gas6 −/− monocytes would be affected. To address the role of Gas6 in the migration of monocytes in response to thrombin, we performed in vitro experiments using Boyden chambers. WT and Gas6 −/− monocytes were incubated with thrombin. Results showed that thrombin increased the migration of WT but not Gas6 −/− monocytes in a CCR2-dependent manner as demonstrated by incubation with a CCR2-blocking antibody ( Figure 3C ).
We subsequently analyzed the role of the CCL2 secreted by endothelial cells to trigger monocyte migration. Conditioned media from WT and Gas6 −/− endothelial cells incubated with thrombin was collected and then incubated with WT monocytes. Using Boyden chambers, we found that conditioned media from thrombin-treated WT but not Gas6 −/− endothelial cells promoted migration of WT monocytes. Incubation with a CCL2-blocking antibody reduced the migration of WT monocytes treated with conditioned media from thrombin-treated WT endothelial cells ( Figure 3D ). Interestingly, we also found that PSGL-1 expression was increased in monocytes incubated with conditioned media from thrombin-treated WT endothelial cells. Incubation with a CCL2 antibody reduced the expression of PSGL-1 in WT monocytes treated with conditioned media ( Figure V in the online-only Data Supplement). These data demonstrate that Gas6 plays an important role in endothelium-mediated monocyte migration through CCR2/ CCL2 interactions and PSGL-1 expression.
Gas6-Dependent CCL2 Expression Is Mediated via JNK
Both Gas6 and thrombin have been shown to activate JNK (c-Jun N-terminal kinase). [23] [24] [25] Thus, we assessed the role of JNK in Gas6-dependent CCL2 expression and monocyte migration. Thrombin treatment induced the phosphorylation of JNK in WT but not in Gas6 −/− endothelial cells ( Figure 4A ). Treatment of WT endothelial cells with SP600125, an inhibitor of JNK, significantly reduced thrombin-induced JNK phosphorylation and CCL2 production ( Figure 4B and 4C) . In Gas6 −/− endothelial cells, thrombin treatment had no effect on JNK phosphorylation or CCL2 production ( Figure 4C) .
To confirm the role of JNK in CCL2 expression, we tested whether inhibition of JNK would reduce monocyte migration.
We collected conditioned media from thrombin-treated WT endothelial cells in the presence or absence of SP600125. In Boyden chambers, conditioned media from thrombin-treated WT endothelial cells promoted the migration of WT monocytes. Monocyte migration was inhibited by conditioned media from WT endothelial cells treated with thrombin and SP600125 ( Figure 4D ). These data suggest that JNK is required for Gas6-mediated CCL2 secretion from endothelial cells thereby promoting monocyte migration.
Discussion
In the current study, we show that Gas6 is required for the recruitment of inflammatory (Ly6C hi CCR2 hi CX 3 CR1 lo ) monocytes, which contribute to venous thrombosis. Gas6 promotes the recruitment of such monocytes through a CCR2/CCL2-dependent mechanism.
Gas6 has been shown to have either pro-or anti-inflammatory effects depending on the disease and the cell type studied. 26 Interestingly, Gas6 has emerged as an important regulator of immune homeostasis by promoting interactions between endothelial cells and leukocytes and leukocyte extravasation in murine models of inflammation (heart transplantation, endotoxinemia, and vasculitis). 21, 27 It was found that IFNα induced the Gas6 receptor, Axl, in monocyte-derived dendritic cells and that Gas6 stimulates the migration of these cells. 28 Gas6 has also been implicated in the migration of neutrophils. 29 Neutrophils have been largely implicated in venous thrombosis especially because the discovery of their capacity to activate coagulation through the formation of NETs (neutrophil extracellular traps). 8, 30, 31 Depletion of neutrophils dramatically reduces venous thrombosis. 8 However, in the present study, we did not find any role for Gas6 regarding neutrophil recruitment. Studies have also demonstrated that monocytes play a crucial role in the pathogenesis of venous thrombosis induced by partial ligation of the inferior vena cava in mice. 8 In agreement with this study, we found that monocytes are recruited early during venous thrombosis formation. We found that Gas6 is specifically involved in the recruitment of monocytes in venous thrombosis induced by FeCl 3 or by flow restriction. To establish the role of monocytes in FeCl 3 -induced venous thrombosis, we first depleted all circulating monocytes in WT mice. We observed that monocyte depletion reduced venous thrombosis, which is consistent with previously published studies. 8, 32 Thus, our results strongly suggest that Gas6 specifically enhances the recruitment of monocytes during venous thrombosis. Several mechanisms have been identified to explain the role of monocytes in DVT. It has been shown that the major source of TF arises from monocytes in the flow restriction model. 8 Although it was not investigated in the present study, one can speculate that monocyte depletion would be associated with a reduction of TF within a thrombus and thus a reduction of activation of the extrinsic pathway of the coagulation cascade. Monocytes can interact with platelets to form monocyte-platelet complexes, which induce platelet activation. 33 However, depletion of monocytes did not modify platelet activation in our study.
Two monocyte subsets, CCR2 hi CX 3 CR1 lo and CX 3 CR1 hi , have been described based on the expression of chemokine receptors. Inflammatory monocyte recruitment occurs in other cardiovascular diseases such as atherosclerosis, 34, 35 myocardial infarction, 36 and hypertension. 37 Interestingly, the loss of Gas6 reduces the recruitment of inflammatory monocyte to the thrombus without affecting the recruitment of patrolling monocytes. Specific depletion of inflammatory monocytes, using a CCR2 antibody, decreases thrombus formation to the same extent as global monocyte depletion. In accordance with our results, CCR2 deficiency was found to be associated with fewer monocytes recruited during DVT. 38 A more recent study demonstrated that Ly6C hi monocytes were recruited in the first 2 days of thrombosis formation after the establishment of flow restriction. 32 Recently, it has been shown that several mediators of innate immune cell trafficking are increased in a murine model of venous thrombosis, among them CCL2, CXCL1, CXCL5, interleukin-6, and P-selectin. Interestingly, it was found that CCL2 expression is increased over time during venous thrombosis induced by flow restriction.
8 CCR2 is the main receptor for CCL2 and has been described to participate in the recruitment of inflammatory monocytes in atherosclerosis. 39 , 40 Thus, we tested in vitro whether Gas6 was required for CCR2 expression from monocytes and CCL2 expression from endothelial cells when treated with thrombin. We found that thrombin induced CCR2 expression in WT but not in Gas6 −/− monocytes. More importantly, we demonstrated that CCR2 was required for thrombin-induced monocyte migration and that this process was Gas6 dependent. In addition, we found that CCL2 expression was increased by thrombin in WT but not in Gas6 −/− endothelial cells. CCL2 secreted by WT endothelial cells was directly associated with an increase of monocyte migration and PSGL-1 expression. Hence, blocking CCL2 in vivo decreases the recruitment of inflammatory monocytes in the thrombus, resulting in the formation of a smaller clot. This is in accordance with a previous study showing that CCL2 blockade reduced monocyte recruitment and neointima formation after wire injury in vivo. 41 In accordance with other studies, we demonstrate that thrombin induces CCL2 and CCR2 expression through PAR-1 activation. [42] [43] [44] Importantly, this study demonstrates that Gas6 is required for thrombin-mediated CCL2 and CCR2 expression in the context of venous thrombosis. Finally, several studies have demonstrated that the expression of CCL2 was regulated by JNK MAP kinase in endothelial cells and adipocytes. [45] [46] [47] Accordingly, we found that Gas6 mediates thrombin-induced expression of CCL2 through the activation of JNK. Overall, the above data extend previous findings that demonstrate that Gas6 and its receptors have a role in inflammation. 21, 48 We previously showed that Gas6 from the hematopoietic and the nonhematopoietic compartments was important for venous thrombosis. 17 Here, we demonstrate that Gas6 contributes to monocyte recruitment through the expression of CCL2 by endothelial cells and the expression of CCR2 by monocytes, which also suggest a contribution of both compartments. Our study emphasizes the role of Gas6 from monocytes and endothelial cells. However, Gas6 is also found in platelets in mice. Platelets are known to support inflammation and interact with endothelial cells, monocytes, and neutrophils. 49 They secrete cytokines stored in α-granules that facilitates leukocyte recruitment. 8, 50 It is possible that the absence of Gas6 in platelets may impair their role in inflammation and monocyte recruitment. Thus, we cannot rule out a role for Gas6 from platelets in our study.
Taken together, our data reinforce the link between inflammation and venous thrombosis by showing that the recruitment of inflammatory monocytes is indispensable in the early stage of venous thrombus formation. Gas6 regulates both inflammatory and thrombotic events. We provide significant insight in the role of Gas6 in the formation of venous thrombosis through inflammatory monocyte recruitment. Deciphering the role of Gas6 and the precise function of inflammatory monocytes in venous thrombosis occurrence can be a powerful tool for the identification of new targets for future antithrombotic therapy.
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